'Rescue' therapies for the management of Helicobacter pylori infection

被引:45
作者
Di Mario, Francesco
Cavallaro, Lucas G.
Scarpignato, Carmelo
机构
[1] Maggiore Univ Hosp, Dept Clin Sci, Gastroenterol Sect, IT-43100 Parma, Italy
[2] Univ Parma, Dept Clin Sci, Gastroenterol Sect, I-43100 Parma, Italy
[3] Univ Parma, Sch Med & Dent, Lab Clin Pharmacol, Dept Anat Pharmacol & Forens Sci, I-43100 Parma, Italy
关键词
Helicobacter pylori infection; Helicobacter pylori eradication; eradication failure; failed eradication attempts; rescue therapies;
D O I
10.1159/000090315
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Helicobacter pylori infection is the main cause of gastritis, gastroduodenal ulcer and gastric cancer and should be considered as a major public health issue. According to several international guidelines, first-line therapy for treating H. pylori infection consists of proton pump inhibitor (PPI) or ranitidine bismuth citrate (RBC) with any two antibiotics of amoxicillin, clarithromycin or metronidazole given for 7-14 days. However, even with the recommended treatment regimens, approximately 20% of patients will fail to obtain H. pylori eradication. The proportion of patients with first-line H. pyloritherapy failure may be higher in clinical practice and it may increase thanks to diffusion of H. pylori treatment. The recommended second-line therapy is the quadruple regimen composed by tetracycline, metronidazole, bismuth salts and a PPI. However, the efficacy of this regimen is limited by poor patient's compliance due to its side effects, number of tablets per day, and long duration. Moreover, bismuth and metronidazole are not available in all countries. Alternatively, a longer-lasting (i.e. 10-14 days) PPI or RBC triple therapy with two antibiotics has generally been used. In an empirical strategy, the choice of second line depends on the treatment initially used. If a clarithromycin-based regimen was administered in first line, a quadruple regimen or PPI (or RBC) triple therapy with metronidazole and amoxicillin (or tetracycline) should be suggested as a second line. In case of second-line treatment failure, the patient should be evaluated by a case-by-case approach. A susceptibility-guided strategy, if available, is recommended in order to choose the best third-line treatment. Culture can reveal the presence of H. pylori-sensitive strains to clarithromycin (the best effective) or other antimicrobials (such as amoxicillin, metronidazole and tetracycline). Conversely, in an empirical strategy, a third-line not yet used therapy, can reach a high success rate. PPI or RBC, amoxicillin and a new antimicrobial (e.g. rifabutin, levofloxacin or furazolidone) could be used. Several studies have obtained relatively good results with triple therapy combining PPI, rifabutin, and amoxicillin, although a reversible myelotoxicity as leukopenia and thrombocytopenia has been described. Preliminary good results were also achieved with triples PPI regimens combining levofloxacin and amoxicillin without important adverse effects. Furazolidone has also shown efficacy for H. pylori eradication, although untoward reactions could limit its use, especially when high doses are employed. Finally, in more than one H. pylori treatment failure, non-antimicrobial add-on medications (such as lactoferrin, probiotics and others) could be used with the aim either to improve the eradication rate or to minimize side effects. Copyright (c) 2006 S. Karger AG, Basel.
引用
收藏
页码:113 / 130
页数:18
相关论文
共 150 条
  • [1] Aldana LP, 2002, HELICOBACTER, V7, P306
  • [2] The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy
    Armuzzi, A
    Cremonini, F
    Bartolozzi, F
    Canducci, F
    Candelli, M
    Ojetti, V
    Cammarota, G
    Anti, M
    De Lorenzo, A
    Pola, P
    Gasbarrini, G
    Gasbarrini, A
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2001, 15 (02) : 163 - 169
  • [3] ARNOLD RR, 1980, INFECT IMMUN, V28, P893
  • [4] The HOMER study:: The effect of increasing the dose of metronidazole when given with omeprazole and amoxicillin to cure Helicobacter pylori infection
    Bardhan, KD
    Bayerdörffer, E
    Van Zanten, SJOV
    Lind, T
    Mégraud, F
    Delchier, JC
    Hellblom, M
    Stubberöd, A
    Burman, CF
    Gromark, PO
    Zeijlon, L
    [J]. HELICOBACTER, 2000, 5 (04) : 196 - 201
  • [5] Helicobacter pylori:: the challenge in therapy
    Bazzoli, F
    Pozzato, P
    Rokkast, T
    [J]. HELICOBACTER, 2002, 7 : 43 - 49
  • [6] Efficacy of Helicobacter pylori eradication therapies: A single centre observational study
    Beales I.L.P.
    [J]. BMC Gastroenterology, 1 (1)
  • [7] A 10-Day Levofloxacin-Based Therapy in Patients With Resistant Helicobacter pylori Infection: A Controlled Trial
    Bilardi, Claudio
    Dulbecco, Pietro
    Zentilin, Patrizia
    Reglioni, Simona
    Iiritano, Elena
    Parodi, Andrea
    Accornero, Laura
    Savarino, Edoardo
    Mansi, Carlo
    Mamone, Mario
    Vigneri, Sergio
    Savarino, Vincenzo
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2004, 2 (11) : 997 - 1002
  • [8] Daily regimen and compliance with treatment - Fewer daily doses and drugs with fewer side effects improve compliance
    Bloom, BS
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2001, 323 (7314): : 647 - 647
  • [9] Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment -: Preliminary experience
    Bock, H
    Koop, H
    Lehn, N
    Heep, M
    [J]. JOURNAL OF CLINICAL GASTROENTEROLOGY, 2000, 31 (03) : 222 - 225
  • [10] Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection
    Boixeda, D
    Bermejo, F
    Martín-De-Argila, C
    López-Sanromán, A
    Defarges, V
    Hernández-Ranz, F
    Milicua, JM
    García-Plaza, A
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (08) : 1457 - 1460